€1.3m · Other round · Agritech · Copenhagen, Denmark
Yngvi Bio, a Copenhagen-based developer of protein crop-protection products, has secured an additional €1.3m from BioInnovation Institute through its Venture House programme. The 18-month programme follows Yngvi Bio's earlier Venture Lab participation and combines capital with continued access to BII's laboratories, offices, advisers and investor network.
The University of Copenhagen spinout is developing proteins intended to control selected agricultural pests while leaving beneficial insects and other species unaffected. Its founders describe the underlying approach as repurposing bacterial contractile injection systems: protein nanomachines that can be engineered to recognise a target insect and deliver a biological payload. Yngvi Bio says it uses AI-assisted protein design and insect genetics to adapt that mechanism for crop protection.
The company will use the Venture House support to advance its product pipeline, regulatory work and field activity. In a company update, Yngvi Bio said it had completed a first Danish field trial with DLF Seeds and moved production to industrial fermentation. Those milestones point towards a route out of the laboratory, but efficacy, selectivity, formulation stability and scalable economics still need to be demonstrated across crops and field conditions.
Field evidence must connect precision with farm economics
Target specificity is the central commercial promise. A product that controls one damaging pest without harming pollinators or other beneficial insects could give growers a more selective alternative to broad-spectrum chemistry. It may also slow the build-up of resistance if the mechanism differs from existing pesticides. But precision creates its own development burden: every target pest requires validated biology, a stable formulation, an application method and evidence that performance survives heat, ultraviolet exposure and variable field conditions.
The 18-month Venture House period therefore has to link scientific progress with a repeatable development process. Industrial fermentation can support lower-cost protein production, while field trials test whether laboratory selectivity translates into useful crop outcomes. Regulatory planning must progress alongside both, because biological origin does not remove the need to prove efficacy, environmental behaviour and safety.
BII's accelerator structure is suited to that transition. Venture House provides follow-on capital and operating support after Venture Lab rather than treating the company as ready for conventional scale-up. For Yngvi Bio, the meaningful next milestone is not simply another candidate protein; it is a field-validated product package that growers, regulators and future commercial partners can assess against existing pest-control options.
